TY  - JOUR
T1  - Feasibility of androgen receptor pathway inhibitors in prostate cancer: impact of comorbidities, age, and concomitant medication use-a multicenter cohort study
TT  - Prostat kanserinde androjen reseptör yolu inhibitörlerinin uygulanabilirliği: komorbiditeler, yaş ve polifarmasinin etkisi-çok merkezli kohort çalışması
AU  - İlhan, Nurullah
AU  - Doğan, Akif
AU  - Çubukçu, Erdem
AU  - Hacıbekiroğlu, İlhan
AU  - Araz, Murat
AU  - Türk, Hacı Mehmet
AU  - Beşiroğlu, Mehmet
AU  - Ökten, İlker Nihat
AU  - Baş, Süleyman
AU  - Tanoğlu, Alpaslan
AU  - Gümüş, Mahmut
PY  - 2025
DA  - October
Y2  - 2025
DO  - 10.32322/jhsm.1795533
JF  - Journal of Health Sciences and Medicine
JO  - J Health Sci Med /JHSM /jhsm
PB  - MediHealth Academy Yayıncılık
WT  - DergiPark
SN  - 2636-8579
SP  - 1155
EP  - 1163
VL  - 8
IS  - 6
LA  - en
AB  - Aims: Androgen receptor pathway inhibitors (ARPIs) have improved outcomes in advanced prostate cancer. Still, evidence regarding their feasibility in older patients with comorbidities and multiple concomitant medications remains limited, as such populations are often underrepresented in clinical trials.Methods: This multicenter, retrospective cohort study included 538 prostate cancer patients diagnosed between January 2021 and November 2023 across seven centers in Turkiye. Demographic, clinical, pathological, and treatment data were extracted from institutional records. Patients were stratified by treatment type [androgen deprivation therapy (ADT), androgen receptor pathway inhibitor (ARPI), chemotherapy (CT)] and by the number of medications used (≥ three vs. <3). The primary outcome was overall survival (OS); secondary outcomes included follow-up duration, tumor grade, and metastatic distribution.Results: The mean age at diagnosis was 70.3 years, and 59.5% of patients had comorbidities. Concomitant medication use of three or more drugs, was observed in 34.4%. Metastatic disease was present in 82.3% of cases, most commonly involving the bone (62.8%). ARPI therapy was administered to 72.7% of patients, ADT alone to 18.6%, and CT to 8.7%. Patients receiving ARPIs had higher comorbidity and concomitant medication rates and more frequent metastases than those receiving ADT. Still, they achieved significantly longer median follow-up (901 vs. 470 days, p<0.001) and prolonged OS. Patients with concomitant medication use of three or more drugs also showed a longer follow-up (1081 vs. 573 days, p<0.001), lower mortality (32.4% vs. 47.3%, p=0.001), and a higher proportion of grade 1 tumors compared with patients using fewer than three medications.Conclusion: In this large real-world cohort, ARPIs were found to be feasible and effective, even in elderly, comorbid, and medication use of three or more patients, supporting their use beyond traditional trial populations.
KW  - Prostate cancer
KW  - ARPI
KW  - comorbidity
KW  - medication
KW  - real-world study
N2  - Amaç: Bu çalışmada, prostat kanserinde androjen reseptör yolu inhibitörlerinin (ARPI) komorbidite ve polifarmasi varlığında uygulanabilirliği değerlendirildi.Yöntem: Yedi merkezden 538 hasta retrospektif olarak incelendi. Tedavi grupları ADT, ARPI ve kemoterapiye göre; ilaç kullanımı ≥3 ve <3 olarak sınıflandırıldı.Bulgular: Hastaların ortalama yaşı 70,3 yıl olup %59,5’inde komorbidite, %34,4’ünde polifarmasi vardı. ARPI alanlarda sağkalım ADT grubuna göre daha uzundu. Polifarmasi grubunda takip süresi daha uzun ve mortalite daha düşüktü.Sonuç: ARPI’ler, yaşlı, komorbid ve polifarmasi hastalarında uygulanabilir ve etkilidir.
CR  - Shrestha S, Shrestha S, Khanal S. Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings. Aging Med (Milton). 2019;2(1):42-49. doi:10. 1002/agm2.12051
CR  - Kardas P, Lichwierowicz A, Urbański F, Chudzyńska E, Czech M, Kardas G. Prevalence of chronic polypharmacy in community-dwelling elderly people in poland: analysis of national real-world database helps to identify high risk group. Front Pharmacol. 2021;12:739740. doi:10. 3389/fphar 2021.739740.
CR  - Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335-1341. doi:10.1200/JCO.2010.31.2330
CR  - Prathap R, Kirubha S, Rajan AT, Manoharan S, Elumalai K. The increasing prevalence of cancer in the elderly: an investigation of epidemiological trends. Aging Med (Milton). 2024;7(4):516-527. doi:10. 1002/agm2.12347
CR  - Feng X, Higa GM, Safarudin F, Sambamoorthi U, Tan X. Potentially inappropriate medication use and associated healthcare utilization and costs among older adults with colorectal, breast, and prostate cancers. J Geriatr Oncol. 2019;10(5):698-704. doi:10.1016/j.jgo.2019.01.012
CR  - Nieder C, Mannsăker B, Pawinski A, Haukland E. Polypharmacy in older patients ≥70 years receiving palliative radiotherapy. Anticancer Res. 2017;37(2):795-799. doi:10.21873/anticanres.11379
CR  - Saad F, Hamilou Z, Lattouf JB. A drug safety evaluation of enzalutamide to treat advanced prostate cancer. Expert Opin Drug Saf. 2021;20(7):741-749. doi:10.1080/14740338.2021.1919620
CR  - Lin YT, Huang YC, Liu CK, Lee TS, Chen M, Chien YN. Treatment-emergent co-morbidities and survival in patients with metastatic castration-resistant prostate cancer receiving abiraterone or enzalutamide. Front Pharmacol. 2021;12:669236. doi:10.3389/fphar 2021.669236
CR  - Shaver AL, Nikita N, Sharma S, et al. The safety of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: an individual-participant data meta-analysis based on 14 randomized clinical trials. Cancers (Basel). 2025;17(17):2747. doi:10.3390/cancers 17172747
CR  - Shen J, Chowdhury S, Agarwal N, et al. Apalutamide efficacy, safety, and wellbeing in older patients with advanced prostate cancer from phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer. 2024; 130(1):73-81. doi:10.1038/s41416-023-02492-8
CR  - Raval AD, Chen S, Littleton N, Constantinovici N, Goebell PJ. Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU Int. 2025;135(3):408-421.  doi:10.1111/bju.16577
CR  - Mir N, Burke O, Yates S, et al. Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review. Ther Adv Med Oncol. 2023;15: 17588359221149887. doi:10.1177/17588359221149887
CR  - Gaber CE, Okpara E, Abdelaziz AI, et al. Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2025;16(2):102148. doi:10.1016/j.jgo.2024.102148
CR  - Bolek H, Yazgan SC, Yekedüz E, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024;9(11):103736. doi:10.1016/j.esmoop.2024.103736
CR  - Roviello G, Cappelletti MR, Zanotti L, et al. Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: a meta-analysis of randomized trials. Medicine (Baltimore). 2016;95(43): e4636. doi:10.1097/MD.0000000000004636
CR  - Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27(2):286-294. doi:10.1093/annonc/mdv542
CR  - George DJ, Ramaswamy K, Yang H, et al. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(4):756-764. doi:10.1038/s41391-024-00816-0
CR  - Merseburger AS, Dornstauder E, Ohlmann CH, et al. Cardiovascular risks and survival with abiraterone vs enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer in Germany: AVENGER study. Adv Ther. 2025;42(4):1919-1934. doi:10.1007/s12325-025-03132-8
CR  - Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2): 121-131. doi:10.1056/NEJMoa1903835
CR  - Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8
CR  - Huang WK, Su PJ, Chen CC, et al. Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan. J Cancer Res Clin Oncol. 2025;151(11):284. doi:10. 1007/s00432-025-06335-2
CR  - La J, Wang L, Corrigan JK, et al. Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer. JAMA Netw Open. 2024;7(8):e2428444. doi:10.1001/jamanetworkopen.2024.28444
CR  - Bahl A, Sodatonou H, Snjider R, et al. Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study. World J Urol. 2024;42(1):584. doi:10.1007/s00345-024-05280-y
CR  - Grace M, Vora T, Estil-Las AA, Arsene C. Severe presentation of de novo type II diabetes in abiraterone and prednisone therapy. Cureus. 2025;17(8):e89841. doi:10.7759/cureus.89841
CR  - Lee YHA, Hui JMH, Leung CH, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis. 2024;27(4):776-782. doi:10.1038/s41391-023-00757-0
UR  - https://doi.org/10.32322/jhsm.1795533
L1  - https://dergipark.org.tr/en/download/article-file/5294006
ER  -